Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2141.2003.04245_4.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rituximab therapy in severe connective tissue disease associated interstitial lung disease: A retrospective single-centre observational study.
Afr J Thorac Crit Care Med
October 2024
Wits Donald Gordon Medical Centre, University of the Witwatersrand, Johannesburg, South Africa.
Background: Connective tissue disease-associated interstitial lung disease (CTD-ILD) that progresses despite first-line immunosuppressive therapy is a clinical challenge. Rituximab (RTX) is a chimeric monoclonal antibody targeted to CD20+ B cells, resulting in B-cell depletion, and has been used as a salvage therapeutic modality in severe disease.
Objectives: To investigate the therapeutic effects and safety of RTX in patients with severe CTD-ILD.
Enlonstobart: First Approval.
Drugs
December 2024
Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Enlonstobart (Enshuxing), a recombinant, fully humanised immunoglobulin G4 monoclonal antibody targeted against programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours. Enlonstobart received its first approval (a conditional marketing authorisation) in June 2024, in China, for use in patients with recurrent or metastatic programmed cell death ligand 1 (PD-L1)-positive cervical cancer who have failed previous platinum-containing chemotherapy. Phase III clinical evaluation of enlonstobart for use as first-line treatment (in combination with chemotherapy ± bevacizumab) in patients with recurrent or metastatic PD-L1-positive cervical cancer is also underway in China.
View Article and Find Full Text PDFAntibody-targeted T cells and natural killer cells for cancer immunotherapy.
J Nanobiotechnology
October 2024
Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK, S7N 5E5, Canada.
Background: Adoptive cell cancer therapies aim to re-engineer a patient's immune cells to mount an anti-cancer response. Chimeric antigen receptor T and natural killer cells have been engineered and proved successful in treating some cancers; however, the genetic methods for engineering are laborious, expensive, and inefficient and can cause severe toxicities when they over-proliferate.
Results: We examined whether the cell-killing capacity of activated T and NK cells could be targeted to cancer cells by anchoring antibodies to their cell surface.
CD64 fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8 T cells.
Gut
November 2024
Pancreas Center, Department of pancreatic cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, National Key laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Key laboratory of Digestive Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, People's Republic of China
Objective: The objective of this study is to improve the efficacy of CLDN18.2/CD3 bispecific T-cell engagers (BiTEs) as a promising immunotherapy against pancreatic ductal adenocarcinoma (PDAC).
Design: Humanised hCD34/hCD3e, Trp53KrasPdx1-Cre (KPC), pancreas-specific Cldn18.
Recent strides in macromolecular targeted photodynamic therapy for cancer.
Curr Opin Chem Biol
August 2024
Department of Bioengineering, University of Texas at Dallas, Richardson, TX, USA. Electronic address:
The recent approval of Akalux® for antibody-targeted photodynamic therapy (PDT) in Japan (also known as photoimmunotherapy), and the recent approval of Cytalux® for folate-specific image guided surgery by the FDA have motivated the continued development of macromolecular targeted PDT for cancer management. This review spotlights some of the most recent advances in macromolecular targeted PDT since 2021, exploring the latest advances in protein engineering, adaptive macromolecular constructs and nanotechnology, adoption of immune checkpoint inhibitors, and targeting using biomimetic membranes. These strategies summarized here attempt to expand the functionality, benefit, and success of macromolecular targeting for PDT to advance the technology beyond what has already entered into the clinical realm.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!